Evidence map›Paper›PMID 36973735›Full record

ArticleJournal of pharmaceutical policy and practice2023

Medication use review: does it have a future and potential in Latvia? The opinion of pharmacists after the pilot project.

Madara Paidere, Jūlija Pavlovska, Ieva Rutkovska, Dace Ķikute, Ieva Salmane-Kuļikovska

Open access · goldFull text read
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Madara PaidereDepartment of Applied Pharmacy, Riga Stradins University, Riga, Latvia. madarapaidereee@gmail.com.ORCID http://orcid.org/0000-0002-1495-5612
Jūlija PavlovskaDepartment of Applied Pharmacy, Riga Stradins University, Riga, Latvia.
Ieva RutkovskaDepartment of Applied Pharmacy, Riga Stradins University, Riga, Latvia.
Dace ĶikutePharmacists' Society of Latvia, Riga, Latvia.
Ieva Salmane-KuļikovskaDepartment of Applied Pharmacy, Riga Stradins University, Riga, Latvia.
Riga Stradiņš University · LVUniversity of Latvia · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven that the Medication Use Review (MUR) can be used as a tool to improve the quality, safety, and appropriate use of medications, it has been implemented in several countries around the world. The MUR pilot project was carried out in Latvia, followed by this study to identify obstacles, favorable factors, and benefits of this service from the perspective of pharmacists, being one of the key stakeholders.

methodsQualitative data were obtained through a semi-structured focus group interview with pharmacists participating in the project. Inductive thematic analysis was performed on transcript to describe potential gains, obstacles, and prerequisites for implementing the MUR service from the pharmacist's perspective.

resultsLack of payment, cooperation with physicians, problems with patient involvement and insufficiency of competence, were identified as the main barriers to implementation of the MUR service as a pharmacist-led service in community pharmacy. However, there were also contributing factors for MUR service, such as the interest of patients and pharmacists involved in the project, the support from the employer, the benefit for physicians, the improvement of patient health literacy and medication adherence.

conclusionsDespite the potential obstacles, the findings in Latvia, as well as other countries, show that the MUR service contributes to the benefit of patients, pharmacists and also physicians; therefore, further steps should be taken to eliminate obstacles and gain additional insights to implement the MUR service in Latvia.

Indexed as

BarriersCommunity pharmacyMedication reviewMURPharmacist

Identifiers

PMID36973735
PMCPMC10044426
OpenAlexW4361018195

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.